Carcinoma, Non-Small-Cell Lung Clinical Trials in Seattle, Washington

6 studies are recruiting for carcinoma, non-small-cell lung in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

   The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Cancer Institute ( Site 0143), Seattle, Washington

   Locations

   242 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06623422 on ClinicalTrials.gov

2. A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

   The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on pr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutchison Cancer Center, Seattle, Washington

   Locations

   67 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06855771 on ClinicalTrials.gov

3. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center, Seattle, Washington

   Locations

   418 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06119581 on ClinicalTrials.gov

4. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

   The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center, Seattle, Washington

   Locations

   369 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06890598 on ClinicalTrials.gov

5. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

   The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characteriz…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Swedish Cancer Institute, Seattle, Washington

   Locations

   110 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05498428 on ClinicalTrials.gov

6. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

   This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Swedish Cancer Institute, Seattle, Washington

   Locations

   158 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04389632 on ClinicalTrials.gov